Genital Warts

Genital warts, also called anogenital warts or condyloma acuminata, are among the most common sexually transmitted infections in the United States, and they are also one of the most misunderstood. This guide is a physician's evidence-based look at what causes genital warts, how they are diagnosed, and how the full menu of CDC-recommended treatments, from patient-applied imiquimod and podofilox to provider-applied cryotherapy and TCA, actually compares on clearance and recurrence. It also covers HPV vaccination, partner communication, and pregnancy considerations. Genital warts are common, treatable, and not a reflection of anyone's character or hygiene. Every material claim below is cited to a primary source.

What Are Genital Warts?

Genital warts are soft, flesh-colored to gray growths that appear on the skin and mucosa of the anogenital region. They range from tiny, barely visible papules to larger, cauliflower-like clusters, and they can appear singly or in groups. In people with a penis, warts most often appear on the shaft, glans, or foreskin. In people with a vulva, warts most often appear on the labia, perineum, and vaginal opening, and can extend internally to the vaginal walls or cervix. Warts can also occur around and inside the anus in anyone who has had receptive anal contact, regardless of gender.^[14]

HPV types 6 and 11

More than 90 percent of visible genital warts are caused by HPV types 6 and 11, which are classified as low-risk or non-oncogenic types.^[4] This is an important and reassuring distinction: the HPV types that cause visible warts are, with rare exceptions, not the same types that drive cervical, anal, or oropharyngeal cancer. High-risk HPV types, most notably 16 and 18, are associated with cancer but only occasionally produce visible warts. A patient diagnosed with genital warts does not need to assume they are at elevated cancer risk from that infection alone, though routine age-appropriate cervical cancer screening remains important regardless of wart history.

Distinguishing genital warts from other lesions

Several benign and normal anatomic variants are commonly mistaken for genital warts, and part of an accurate diagnosis is ruling these out. Pearly penile papules (small, uniform, dome-shaped bumps arranged in rows around the corona of the glans) are a normal anatomic variant, not a wart or infection. Vestibular papillae (small, symmetric, soft projections on the inner labia minora) are similarly a normal variant in people with a vulva. Molluscum contagiosum, caused by a different virus, presents as small, dome-shaped papules with a characteristic central dimple (umbilication). Skin tags, sebaceous cysts, and condyloma lata (a manifestation of secondary syphilis, which are broader and flatter than typical warts) round out the differential.^[14] A clinician experienced in genital dermatology can usually distinguish these on visual inspection alone.

Prevalence and transmission

Genital HPV infection is extremely common, most sexually active adults are exposed to at least one HPV type during their lifetime, but only a minority of those infected with wart-causing types go on to develop visible lesions. HPV is transmitted through skin-to-skin and mucosal contact during vaginal, anal, or oral sexual activity, and importantly, transmission can occur even without penetrative intercourse and even when no visible warts are present, since the virus can be shed subclinically.^[1] Condoms reduce but do not eliminate transmission risk, because they do not cover all potentially infected skin. The incubation period, the time between exposure and the appearance of visible warts, is variable and can range from a few weeks to many months or longer, which makes it difficult to identify exactly when or from whom the infection was acquired.

Diagnosis: How Warts Are Identified

Visual inspection is usually enough

Genital warts are typically diagnosed by visual inspection alone. An experienced clinician can usually identify the characteristic appearance, soft, flesh-toned to gray, verrucous (cauliflower-like) or smooth papules, often in clusters, without additional testing.^[1] Applying dilute acetic acid (vinegar) to turn HPV-infected tissue white, a technique called acetowhitening, is sometimes used to help delineate the extent of subclinical infection, particularly before a procedural treatment, but it is not specific to HPV and can produce false positives from other causes of irritation, so it is used as an adjunct rather than a definitive test.

When to biopsy

Biopsy is not routinely needed but is recommended when the diagnosis is uncertain, when lesions do not respond to standard treatment, when lesions appear atypical (pigmented, indurated, fixed to underlying tissue, ulcerated, or bleeding), or in immunocompromised patients, in whom atypical presentations and dysplastic or malignant changes are more common.^[1] Any lesion with these atypical features should be biopsied to rule out vulvar, penile, or anal intraepithelial neoplasia or squamous cell carcinoma before proceeding with standard wart treatment.

STI co-screening

Because genital warts are a sexually transmitted infection, a diagnosis of genital warts is an appropriate trigger to offer screening for other STIs, including chlamydia, gonorrhea, syphilis, and HIV, particularly if the patient has not been recently screened or has other risk factors.^[1] This is standard, non-judgmental practice, not a reflection of assumptions about the patient's behavior, and mirrors the comprehensive sexual health screening recommended for anyone newly diagnosed with any STI.

What's Changed in 2024 to 2026

Genital wart management has been relatively stable over the past several years compared with faster-moving fields, but there have been meaningful shifts in vaccination policy, investigational treatments, and access.

HPV vaccination is now approved through age 45. Gardasil 9 was originally approved for ages 9 through 26, and the FDA expanded approval to include adults through age 45 based on data showing continued benefit in previously unvaccinated or partially vaccinated adults, provided they are shared-decision-making candidates with their clinician about likely benefit given prior HPV exposure history.^[12] This has meaningfully expanded who can be offered vaccination, particularly adults who missed the original catch-up window.

Sofdra and cidofovir remain investigational for genital warts specifically. Sofdra (sofpironium bromide) is FDA-approved for hyperhidrosis, not genital warts, and topical cidofovir remains an off-label, investigational option used mainly for treatment-refractory or immunocompromised cases under specialist supervision. Neither has supplanted the CDC-recommended first-line menu, and patients should be cautious about off-label or unproven options marketed for genital warts specifically.

Telehealth prescribing has normalized further. Imiquimod, podofilox, and sinecatechins can all be prescribed through a synchronous telehealth visit in all 50 U.S. states following a history and, when feasible, photo-assisted visual assessment, lowering the friction for patients who might otherwise delay care due to embarrassment. Provider-applied treatments, cryotherapy, TCA, and surgical options, still require an in-person visit.

Taken together, these changes have not altered the fundamental treatment menu, the CDC's patient-applied and provider-applied categories remain the backbone of care, but they have expanded vaccination eligibility and made the first step of care, getting a prescription for a patient-applied topical, easier to access without an in-person visit.

Decision Framework: How to Choose a Treatment

Choosing a genital wart treatment depends primarily on wart location, extent of disease, patient preference for a self-applied versus office-based option, cost, and, for people who can become pregnant, pregnancy status. The table below summarizes location-based preferences drawn from CDC guidance and clinical practice.^[1]

Beyond location, patients weighing a patient-applied versus provider-applied approach should consider that patient-applied treatments require weeks of consistent adherence but no office visits, while provider-applied treatments achieve faster single-session or short-course clearance but require repeat visits and, for cryotherapy and TCA, can be uncomfortable during application. Neither category is universally superior; the right choice is the one a given patient will use consistently and can access.

Patient-Applied Treatments

Imiquimod 5% cream

Imiquimod is an immune-response modifier that works by activating toll-like receptor 7 (TLR-7) on local immune cells, triggering release of interferon-alpha and other cytokines that mount a local immune response against HPV-infected cells.^[2] This mechanism is fundamentally different from the destructive or antimitotic mechanisms of other treatments, and it is part of why imiquimod tends to have a lower recurrence rate: it engages the immune system against the virus itself, not just the visible lesion.

A quantitative systematic review of randomized trials found complete clearance in approximately 51 percent of imiquimod-treated patients compared with about 14 percent with placebo, a number needed to treat of roughly 2.2 patients to achieve one additional clearance.^[2] An earlier pivotal multicenter trial of self-administered topical imiquimod similarly found substantially higher clearance than vehicle cream, with women achieving higher clearance rates than men in most trials, possibly reflecting differences in genital skin thickness and keratinization.^[6] Standard dosing is application three times per week (for example, Monday, Wednesday, Friday), left on the skin for 6 to 10 hours before washing off, continued for up to 16 weeks or until warts clear, whichever comes first.

Podofilox 0.5% solution or gel

Podofilox is an antimitotic agent that causes direct necrosis of wart tissue by disrupting cell division.^[1] It works faster than imiquimod because its mechanism is directly destructive rather than immune-mediated, but this same mechanism means it does not address latent virus in surrounding skin as effectively, contributing to its higher recurrence rate of approximately 38 percent. Clearance rates run around 45 percent. The standard regimen is application twice daily for 3 consecutive days, followed by 4 days with no treatment, repeated for up to 4 cycles. Podofilox is applied only to visible warts, using a cotton swab or, depending on formulation, a fingertip with subsequent handwashing, and it should not be used on mucosal surfaces (vaginal or anal canal) due to higher absorption and irritation risk in these areas.

Sinecatechins 15% ointment

Sinecatechins (brand name Veregen) is a botanical drug derived from green tea leaf extract, standardized to a defined mixture of catechins, most notably epigallocatechin gallate.^[8] Its mechanism is thought to involve antioxidant activity and induction of apoptosis (programmed cell death) in HPV-infected cells, along with local immunomodulatory effects. A randomized controlled trial in patients with external anogenital warts found complete clearance in approximately 57 percent of sinecatechins-treated patients, with recurrence at 12 weeks post-treatment of only about 7 percent, the lowest of any topical agent studied.^[3] The standard regimen is application three times daily (a thin layer to each wart, without washing off) for up to 16 weeks. Because sinecatechins is generally well tolerated with predominantly mild local skin reactions, it has become an attractive option for patients who experienced significant irritation with imiquimod or podofilox.

Provider-Applied Treatments

Cryotherapy

Cryotherapy uses liquid nitrogen, applied with a spray device or cotton-tipped applicator, to freeze wart tissue, causing cytolysis (cell death from ice crystal formation) and a localized inflammatory response that helps clear both the treated wart and, to some degree, subclinical HPV in the surrounding margin.^[7] Clearance rates run approximately 75 percent, among the highest of single-modality treatments, typically achieved over 1 to 3 sessions spaced 1 to 2 weeks apart. A comparative trial found cryotherapy and TCA had broadly similar efficacy, with cryotherapy showing a modest edge in some outcome measures.^[7] Local discomfort during and shortly after treatment, blistering, and temporary skin discoloration are the main tolerability considerations, and cryotherapy requires an in-person visit with appropriately trained staff and equipment.

Trichloroacetic acid (TCA) or bichloroacetic acid (BCA)

TCA and BCA are caustic acids, typically used at 80 to 90 percent concentration, that work by chemically coagulating (denaturing) proteins in wart tissue, causing localized tissue destruction.^[1] They are applied precisely to the wart surface with a fine applicator, taking care to avoid surrounding healthy skin, and allowed to dry before the patient stands or sits again. Clearance rates run approximately 70 percent with weekly application for up to 6 weeks. TCA and BCA are notably safe in pregnancy, which makes them a preferred provider-applied option when topical prescription creams are contraindicated. A burning sensation during and immediately after application is expected and typically resolves within minutes to hours.

Surgical options: curettage, electrosurgery, laser

Surgical excision (scissor or shave excision with local anesthesia), electrosurgery (thermal ablation using an electrocautery device), and CO2 laser ablation are mechanical or thermal removal techniques that achieve the highest single-session clearance rates, approximately 90 percent, and are the fastest route to visibly wart-free skin.^[1] These options are generally reserved for extensive wart burden, warts resistant to topical or cryotherapy treatment, or cases where a tissue sample is simultaneously needed for pathology. They require local or, for extensive disease, general anesthesia, carry a modest risk of scarring, and are typically performed by a dermatologist, gynecologist, or surgeon rather than a primary care clinician.

Head-to-Head: How the Treatments Compare

The table below summarizes clearance rate, recurrence rate, mechanism, and typical course for every CDC-recommended treatment, drawn from the systematic reviews and trials cited throughout this guide.^[1][2][3]

Recurrence: The Persistent Challenge

Why warts recur

Every genital wart treatment, patient-applied or provider-applied, works by destroying or immunologically clearing visible wart tissue. None of them eliminate HPV from the surrounding, visually normal skin, where the virus can persist in a latent or subclinical state.^[1] This is the central reason recurrence rates across all treatment categories run from roughly 30 to 70 percent within 3 to 6 months of apparent clearance: the immune system, not the treatment itself, is ultimately what clears latent virus, and that process can take months to years, or in some individuals may never fully happen.

Which treatments have the lowest recurrence

The pattern across the evidence is consistent: treatments that engage the immune system, imiquimod and sinecatechins, have meaningfully lower recurrence (13 percent and 7 percent, respectively) than purely destructive treatments like cryotherapy, TCA, podofilox, or excision (30 to 40 percent).^[2][3] This does not mean immune-modulating agents are always the better first choice, destructive treatments still clear warts faster and are sometimes necessary for extensive disease, but it is a relevant consideration when a patient's priority is minimizing the chance of needing retreatment.

When to retreat

Recurrent warts after apparently successful treatment are common and are not a sign that the first treatment failed or that something is wrong with the patient's immune system. Retreatment with the same or a different agent is standard practice, and many patients need more than one course of therapy over time before warts resolve durably. Combination approaches, for example provider-applied treatment for visible warts followed by a maintenance course of imiquimod or sinecatechins, are sometimes used for patients with a pattern of frequent recurrence, though comparative trial data on combination regimens specifically is limited.

HPV Vaccination: Prevention Is the Cure

Gardasil 9 coverage

Gardasil 9 is the only HPV vaccine currently available in the United States and protects against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58.^[4] Types 6 and 11 are the two types responsible for approximately 90 percent of genital warts, which means Gardasil 9 is, in effect, a highly effective vaccine against genital warts specifically, in addition to its role in preventing cervical, anal, and other HPV-associated cancers caused by the high-risk types it also covers.

Adult catch-up vaccination

The Advisory Committee on Immunization Practices recommends shared clinical decision-making about HPV vaccination for adults aged 27 through 45 who were not adequately vaccinated earlier, since most adults in this range have already had some sexual exposure, and vaccine benefit is lower for HPV types the person has already encountered but still meaningful protection against types not yet acquired.^[12] A patient who has already had genital warts is not excluded from vaccination and may still benefit by gaining protection against HPV types, including high-risk oncogenic types, they have not yet been exposed to.

Vaccine impact on genital wart incidence

Population-level surveillance from countries with high vaccination uptake has documented dramatic declines in genital wart diagnoses among young, vaccinated cohorts, with national Australian surveillance data showing genital wart diagnoses in young women falling by more than 80 percent within 5 years of the national vaccination program's start, along with a substantial decline in young heterosexual men attributable to herd immunity.^[11] A decade of US surveillance similarly found substantial declines in HPV-associated disease among vaccinated cohorts.^[10]

Partner Notification and Testing

Telling a current or recent partner about a genital wart diagnosis is a reasonable and often recommended step, but it comes with more nuance than for some other STIs. Because HPV is extremely common, can remain subclinical for years, and there is no routine, reliable test to determine when a person was infected or by whom, partner notification is about shared awareness and shared decision-making rather than establishing blame or a precise transmission timeline.^[1]

There is no CDC-recommended blood test or swab test to screen an asymptomatic partner for genital HPV; visual inspection when symptoms or visible warts are present is the primary method of evaluation, and partners without visible warts do not require treatment.^[1] This has been the consistent clinical approach to genital wart management for decades: treat visible disease, and do not pursue testing or treatment of an asymptomatic partner in the absence of visible lesions.^[13] A useful, non-alarming way to raise the topic is to frame it as routine sexual health information sharing: "I was diagnosed with genital warts, which is caused by a very common virus called HPV. You don't need to be tested unless you notice any bumps or changes, but I wanted you to know." Partners who are not already vaccinated against HPV can discuss vaccination with their own clinician, which may reduce their risk of future infection with the same or other HPV types.

Pregnancy and Genital Warts

Genital warts can grow larger and more numerous during pregnancy due to pregnancy-related immune and hormonal changes, and existing warts sometimes become newly noticeable for the first time during this period.^[1] Treatment decisions during pregnancy require particular attention to medication safety, since several standard topical treatments are not appropriate for use during pregnancy.

Vaginal delivery is not contraindicated by the presence of genital warts in most cases, and cesarean delivery is not routinely recommended solely because of genital warts; it is reserved for situations where warts are large enough to obstruct the birth canal or would be expected to cause excessive bleeding with vaginal delivery.^[1] Vertical transmission of HPV from mother to newborn during vaginal delivery is possible but uncommon, and the rare resulting condition, recurrent respiratory papillomatosis (HPV-related growths in a child's airway), is sufficiently rare that it does not, on its own, justify routine cesarean delivery for maternal genital warts. Decisions about delivery mode should be individualized with the patient's obstetric team based on wart size, location, and extent.

What Doesn't Work: Home Remedies and OTC Claims

No over-the-counter wart remover, herbal supplement, or "natural" remedy marketed for genital warts has rigorous clinical trial evidence supporting its use on genital or anal skin. This is an area where unproven products circulate widely, in part because genital warts are a condition patients often want to address privately without a clinical visit.

Do not use OTC wart removers on genital skin. Over-the-counter salicylic acid wart removers, sold for common skin warts on hands and feet, are formulated for thicker, non-mucosal skin and are not intended for use on genital or anal skin. They can cause significant chemical burns and tissue damage on this thinner, more sensitive skin, and should never be substituted for the CDC-recommended treatments described in this guide.

A brief evidence summary of commonly marketed non-prescription approaches for genital warts:

• Duct tape occlusion: has limited evidence for common skin warts on hands and feet but no controlled trial evidence for genital warts, and is not recommended for use on genital or anal skin
• Apple cider vinegar or tea tree oil applied directly: no controlled trial evidence of efficacy and meaningful risk of chemical irritation or burns on sensitive genital skin
• Oral immune-boosting supplements: no plausible mechanism specific to HPV clearance and no trial evidence supporting use for genital warts
• Salicylic acid OTC wart removers: formulated for keratinized skin on hands and feet; risk of significant burns if used on genital or anal skin
• Waiting without any evaluation: while some genital warts do resolve without treatment as the immune system eventually clears the virus, this can take months to years, and skipping evaluation also means missing the opportunity to rule out atypical or concerning lesions and to discuss STI co-screening and partner considerations

The takeaway: effective genital wart treatment is well established, several options are accessible via telehealth without the delay or cost of unproven alternatives, and self-treatment with products designed for other types of skin warts carries real risk of harm on genital tissue.

Red Flags: When to See a Clinician Urgently

Most genital warts are a benign, common, and manageable condition that does not require urgent care. However, certain features warrant prompt evaluation rather than routine, scheduled care:

• Bleeding, ulceration, or a lesion that is fixed to underlying tissue, which can indicate a need for biopsy to rule out dysplasia or malignancy rather than a typical wart
• Rapidly growing or unusually large lesions, particularly in an immunocompromised patient, where atypical growth patterns and malignant transformation are more of a concern
• Signs of secondary bacterial infection around a wart or treatment site, including increasing pain, spreading redness, warmth, or pus
• Urinary obstruction or difficulty urinating, which can occur with warts near or within the urethral meatus and warrants prompt urologic evaluation
• Warts appearing for the first time in a person with known HIV or other significant immunocompromise, since atypical presentations and treatment resistance are more common and closer specialist follow-up is often warranted
• Any new pigmented, indurated, or unusual-appearing genital lesion that does not fit the classic appearance of a wart, which should be evaluated before assuming a wart diagnosis

None of these red flags are typical of straightforward genital warts, which are usually soft, mobile, non-tender, and slow-growing. Any significant deviation from that pattern is worth a prompt clinical evaluation rather than continuing with standard, at-home wart treatment.

Frequently Asked Questions